TY  - JOUR
A1  - Aido, Ahmed
A1  - Zaitseva, Olena
A1  - Wajant, Harald
A1  - Buzgo, Matej
A1  - Simaite, Aiva
T1  - Anti-Fn14 antibody-conjugated nanoparticles display membrane TWEAK-like agonism
JF  - Pharmaceutics
N2  - Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
KW  - Fn14
KW  - nanoparticles
KW  - surface modification
KW  - drug-delivery
KW  - anti-TNFRSF receptor (TNFR) antibodies
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242710
SN  - 1999-4923
VL  - 13
IS  - 7
ER  -